pyrroles has been researched along with Lung Diseases, Interstitial in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballerie, A; Batteux, F; Fardel, O; Jego, P; Jeljeli, M; Jouneau, S; Lecureur, V; Lelong, M; Lescoat, A; Morzadec, C; Piquet-Pellorce, C; Vernhet, L | 1 |
| Cardiel, MH; Castañeda, O; Chartrand, S; Citera, G; Fischer, A; Girard, T; Kwok, K; Madariaga, H; Mysler, E; Park, JK; Ponce de Leon, D; Richette, P; Rivas, JL; Strengholt, S; Thorat, AV; Wang, L | 1 |
| Arai, S; Arima, M; Kurasawa, K; Maezawa, R; Namiki, Y; Owada, T; Takamura, Y; Tanaka, A | 1 |
| Agarwal, P; Frye, BC; May, AM; Rizzi, M; Thiel, J; Venhoff, N; Voll, RE; Wendel, S | 1 |
| Chen, Z; Wang, X; Ye, S | 1 |
| Morinobu, A; Nishimura, K; Saegusa, J; Sendo, S; Yamada, H | 1 |
| Ishii, H; Kadota, J; Kushima, H | 1 |
| Adam, M; Eichelberg, C; Fuehner, T; Ganser, A; Grünwald, V; Herrmann, E; Ivanyi, P; Merseburger, AS | 1 |
| Loong, HH; Yeo, W | 1 |
| Hirooka, N; Iwasaki, A; Matsuyama, S; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F | 1 |
1 trial(s) available for pyrroles and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Topics: Adult; Autoantibodies; Dermatomyositis; Drug Therapy, Combination; Female; Glucocorticoids; Historically Controlled Study; Humans; Interferon-Induced Helicase, IFIH1; Janus Kinase Inhibitors; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2019 |
9 other study(ies) available for pyrroles and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Chemokine CXCL13; Female; Gene Expression Regulation; Hypochlorous Acid; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Lung; Lung Diseases, Interstitial; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Nitriles; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Immunologic; Scleroderma, Systemic; Suppressor of Cytokine Signaling 3 Protein | 2020 |
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Lung Diseases, Interstitial; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Topics: Adult; Aged; Dermatomyositis; Drug Therapy, Combination; Female; Ferritins; Glucocorticoids; Humans; Interferon-Induced Helicase, IFIH1; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Survival Rate; Treatment Outcome | 2018 |
Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Topics: Calcinosis; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; MAP Kinase Kinase 4; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2019 |
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dendritic Cells; Disease Models, Animal; Immunity, Innate; Lung Diseases, Interstitial; Male; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Th17 Cells | 2019 |
Sunitinib-related interstitial pneumonia after treatment with temsirolimus: a case of possible recall phenomenon.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Radiography; Sirolimus; Sunitinib | 2014 |
Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sunitinib | 2014 |
Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Indoles; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
[A case of interstitial lung disease due to sunitinib].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib | 2012 |